Aurora Cannabis Inc ACB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Aurora Cannabis Announces Fiscal 2027 Second Quarter Results
Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis
Organigram to Acquire Aurora and Establish a Global Cannabis Leader
Aurora Cannabis to Host Second Quarter 2027 Investor Conference Call
Aurora Cannabis Announces the Alberta Securities Commission has dismissed Curaleaf's Application and ruled in favour of the Company's At-the-Market Program
Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside
Aurora Completes Major Expansion of European EU-GMP Manufacturing Facility, More Than Doubling Expected Annual Flower Output
Aurora Urges Shareholders to Take No Action to Revised Hostile Bid by Curaleaf as Formal Review Underway
Trading Information
- Previous Close Price
- CA$7.24
- Day Range
- CA$7.19–7.27
- 52-Week Range
- CA$3.59–8.75
- Bid/Ask
- CA$7.19 / CA$7.27
- Shares Outstanding
- 65.74M
- Market Cap
- CA$475.33M
- Volume/Avg
- 319,423 / 477,989
Key Statistics
- Price/Earnings (Normalized)
- 28.69
- Price/Sales
- 1.53
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aurora Cannabis Inc is focused on the production, distribution, and sale of cannabis products in Canada and internationally. The Company conducts the production, distribution, and sale of medical cannabis products and, on a very limited basis, consumer cannabis products in Canada pursuant to the Cannabis Act; the production and distribution of wholesale medical cannabis in the European Union pursuant to the German Medicinal Products Act and German Narcotic Drugs Act; and the distribution of wholesale medical cannabis in various international markets, including Australia and New Zealand. Its segments are Canadian Cannabis CGU, European Cannabis CGU, Australia Cannabis CGU, and New Zealand Cannabis CGU, with Canada generating majority revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,101
- Website
- https://www.auroramj.com
Valuation
Metric | ACB |
|---|---|
Price/Earnings (Normalized) | 28.69 |
Price/Book Value | 0.92 |
Price/Sales | 1.53 |
Price/Cash Flow | — |
Price/Earnings
ACB
Financial Strength
Metric | ACB |
|---|---|
Quick Ratio | 1.81 |
Current Ratio | 5.00 |
Interest Coverage | — |
Quick Ratio
ACB
Profitability
Metric | ACB |
|---|---|
Return on Assets (Normalized) | 2.93% |
Return on Equity (Normalized) | 3.75% |
Return on Invested Capital (Normalized) | 2.49% |
Return on Assets
ACB
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|l^PpFyN# | LOCK|dW&^ | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|S?q!JwM | LOCK|D&@# | $50B | |||
| Haleon PLC ADR HLN | LOCK|!bsM!T | LOCK|B<s | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|SD>Sg%h? | LOCK|Z< | $34B | |||
| Viatris Inc VTRS | LOCK|R&>H^$ | LOCK|w@ | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|%c^ | LOCK|&hk | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|#ZXdjkB | LOCK|?s^ | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|YnRyVM | LOCK|@s | $4B | |||
| Perrigo Co PLC PRGO | LOCK|B^Y%Wk | LOCK|p! | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|S@c@cF | LOCK|^HPX | $2B |
United States